228328 - Hearing Impairment (Answered)

Mr Christopher Chope
To ask the Secretary of State for Health, pursuant to his Answer of 17 March 2015 to Question 227433, for what reasons NICE has scheduled development of the clinical guidelines to begin in 2016 and not earlier; and if he will take steps to expedite that process.

George Freeman

It is for NHS England to agree the prioritisation of the development of clinical guidelines in collaboration with the National Institute for Health and Care Excellence (NICE).

227938 - Prostate Cancer: Drugs (Answered)

Mrs Anne Main
To ask the Secretary of State for Health, what assessment he has made of the impact on prostate cancer patients of the delisting of the drug cabazitaxel by the Cancer Drugs Fund; what steps NHS England plans to take to maintain access to cabazitaxel for prostate cancer patients until it has been subject to review by NICE; and what assessment he has made of the effectiveness of the Individual Funding Request process for cancer drugs.

George Freeman

227939 - Gastrointestinal Cancer: Drugs (Answered)

Mrs Anne Main
To ask the Secretary of State for Health, what assessment he has made of the effect on gastrointestinal stromal tumour (GIST) patients of the delisting of the drug regorafenib by the Cancer Drugs Fund; and what steps he is taking to ensure that GIST patients have access to appropriate drugs and treatment.

George Freeman

227776 - Cancer: Drugs (Answered)

Sir David Amess
To ask the Secretary of State for Health, what discussions NHS England has had with manufacturers on alternative commissioning arrangements for treatments that have been removed from the Cancer Drugs Fund list.

George Freeman

NHS England has advised that, since the removal of a number of drugs from the national Cancer Drugs Fund list on 12 March 2015, representatives of NHS England have had preliminary discussions at the request of one manufacturer around maintaining access to one of the drugs removed from the list.

228320 - Prescriptions: Fees and Charges (Answered)

Toby Perkins
To ask the Secretary of State for Health, what the change in prescription charges has been in real terms in each year since 2009-10.

George Freeman

Information is provided in the table.

Annual prescription charge increase per item dispensed, in England, in real terms, 2009 to 2015

2009/10

2010/11

2011/12

2012/13

2013/14

2014/15

227588 - Macular Degeneration (Answered)

John Glen
To ask the Secretary of State for Health, when officials of his Department last discussed unlicensed treatments for age-related macular degeneration with (a) the Medicines and Healthcare products Regulatory Agency and (b) the General Medical Council; what the content of those discussions was; and if he will make a statement.

George Freeman

227587 - Macular Degeneration (Answered)

John Glen
To ask the Secretary of State for Health, what correspondence his Department has had with NHS England in the last two months on the use of unlicensed treatments for age-related macular degeneration; and if he will place copies of such correspondence in the Library.

George Freeman

227586 - Pharmaceutical Price Regulation Scheme (Answered)

John Glen
To ask the Secretary of State for Health, what his most recent estimate is of the rebate which will be paid to the Exchequer in 2015-16 through the Pharmaceutical Price Regulation Scheme; what assessment he has made of the potential effect of greater use of unlicensed medicines for age-related macular degeneration on that rebate; and if he will make a statement.

George Freeman

228482 - Innovative Medicines and Medical Technology Review (Answered)

Neil Parish
To ask the Secretary of State for Health, what progress the Government is making in implementing the recommendations in his Department's Innovative Medicines Review.

George Freeman

The Accelerated Access review into innovative medicines and medical technologies was launched on 20 November 2014. On 11 March, the Government published the review’s terms of reference and announced that Sir Hugh Taylor, Chair of Guys and St Thomas’s NHS Foundation Trust, will chair the review. The review will produce an interim report before the autumn.

228500 - Cancer: Drugs (Answered)

Mr Jamie Reed
To ask the Secretary of State for Health, whether the Government has announced that the Cancer Drugs Fund will continue beyond April 2016.

George Freeman

In August 2014, we announced £80 million in additional funding for the Cancer Drugs Fund for 2015-16. We have made no announcements regarding the Fund for beyond April 2016.

NHS England announced in January 2015 that it plans to increase the level of investment for drugs in the Fund to an expected £340 million in 2015-16.

Pages